US hospitals turn down remdesivir, limit use to sickest COVID patients

Sun Online Desk

13th September, 2020 02:43:44 printer

US hospitals turn down remdesivir, limit use to sickest COVID patients

 

 

US hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed on Friday.

Some hospitals said they are still buying the Gilead Sciences GILD.O medicine to build inventory in case the pandemic accelerates over the winter. But they said current supplies are adequate, in part because they are limiting use to severely ill patients.

The Food and Drug Administration has allowed more liberal remdesivir use, but six out of eight major hospital systems said they were not using it for moderate cases.

The slowdown suggests that a shortage of the drug is over and threatens Gilead’s efforts to expand use of remdesivir, which it sells under the brand name Veklury in some countries.

An HHS spokesperson confirmed on Friday that between July 6 and September 8, state and territory public health systems accepted about 72% of the remdesivir they were offered.

Hospitals in turn purchased only about two-thirds of what states and territories accepted, said Michael Ganio, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists.

Gilead did not respond to a request for comment.

A surplus of remdesivir - which costs $3,120 for a 6-vial intravenous course - marks a turnaround from earlier in the pandemic, when supplies of the drug had fallen short of demand in some regions.

Government-led distribution of remdesivir will expire at the end of September.

Remdesivir was first authorized by the FDA in May for emergency use in COVID-19 patients hospitalized and on oxygen support after data showed it helped shorten hospital recovery time.

(Times of India)

 

 


Top